MedTrace Logo

MSC for Occlusive Disease of the Kidney

NCT01840540 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2017-08-07

No results posted yet for this study

Summary

To determine the safety and toxicity of intra-arterial infused autologous adipose derived mesenchymal stromal (stem) cells in patients with vascular occlusive disease of the kidney.

Conditions

  • Atherosclerotic Renal Artery Stenosis
  • Ischemic Nephropathy
  • Renovascular Hypertension

Interventions

DRUG

Arterial infusion of autologous mesenchymal stem cells

Sponsors & Collaborators

Principal Investigators

  • Stephen Textor, MD · Mayo Clinic

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-04-30
Primary Completion
2014-03-31
Completion
2017-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01840540 on ClinicalTrials.gov